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Abstract
Background: Understanding the pathophysiology of chemokine secretion in endometriosis may
offer a novel area of therapeutic intervention. This study aimed to identify chemokines differentially
expressed in epithelial glands in eutopic endometrium from normal women and those with
endometriosis, and to establish the expression profiles of key chemokines in endometriotic lesions.
Methods: Laser capture microdissection isolated epithelial glands from endometrial eutopic tissue
from women with and without endometriosis in the mid-secretory phase of their menstrual cycles.
Gene profiling of the excised glands used a human chemokine and receptor cDNA array. Selected
chemokines were further examined using real-time PCR and immunohistochemistry.
Results:  22 chemokine/receptor genes were upregulated and two downregulated in pooled
endometrial epithelium of women with endometriosis compared with controls. CCL16 and CCL21
mRNA was confirmed as elevated in some women with endometriosis compared to controls on
individual samples. Immunoreactive CCL16 and CCL21 were predominantly confined to glands in
eutopic and ectopic endometrium: leukocytes also stained. Immunoreactive CCL16 was overall
higher in glands in ectopic vs. eutopic endometrium from the same woman (P < 0.05). Staining for
CCL16 and CCL21 was highly correlated in individual tissues.
Conclusion: This study provides novel candidate molecules and suggests a potential local role for
CCL16 and CCL21 as mediators contributing to the inflammatory events associated with
endometriosis.
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Background
Endometriosis is defined as the ectopic growth of
endometrium-like tissue in locations outside the uterus
including the ovaries, the uterine ligaments, the pelvic
peritoneum, the Fallopian tubes and the external surface
of the uterus. The mechanism/s by which endometriosis
develops is still much debated; however retrograde men-
struation and subsequent tissue persistence and prolifera-
tion is the most accepted theory. The complex question,
why some women and not others, develop endometriotic
lesions is likely to be due to differences in the local regu-
lation of tissue proliferation, tissue remodelling and
inflammatory processes. These observations also raise the
question whether the current practice of prompt surgical
or medical treatment is always appropriate.
Current evidence suggests that endometriosis-related pain
and infertility result from local inflammation at the
implant sites, with chemokine-induced recruitment and
activation of immune cells [1]. Whilst some chemokines
are produced constitutively, the majority (such as CXCL8
(IL-8) and CCL2 (MCP-1)) are induced upon cellular acti-
vation by inflammatory stimuli [2-9]. Constitutively
expressed chemokines are believed to play a role in basal
leukocyte trafficking and secondary lymphoid organ
development while induced chemokines help marshal
inflammatory, immune and angiogenic responses of the
host [10-12]. It is now well established that chemokines
also play a role in inflammatory pain sensation (nocicep-
tion) and cell growth [13]. They are also pivotal in
decreased immunologic surveillance, recognition and
destruction of ectopic endometrial cells and perhaps facil-
itation of the implantation of ectopic endometrial tissues
[14,15].
It is likely that the cascade of proinflammatory proteins
secreted from endometriotic lesions and associated
immune cells, dictate the extent of the inflammatory reac-
tion linked with endometriosis, either by facilitating the
survival of these lesions or by leading to their demise.
Chemokines have been demonstrated to upregulate adhe-
sion molecules and promote invasion of cancer cells [15-
18]. Such actions could potentially facilitate the attach-
ment and invasion of epithelial cells into the ectopic sites,
as observed in cancer metastasis [19]. A number of chem-
okines have previously been implicated as mediators in
the ontogenesis of endometriosis [20]. The levels of
monocyte chemotactic protein-1 (MCP-1/CCL2) [7,8];
regulated on activation normal T-expressed and secreted
(RANTES/CCL5) [21]; interleukin-8 (IL-8/CXCL8)
[22,23]; and growth-regulated oncogene-α (GROα/
CXCL1) [24] are elevated in the peritoneal fluid of women
with endometriosis, and their concentrations correlate
with the stage of the disease. Natural Killer (NK) cell activ-
ity is also mediated by chemokines and is decreased in
patients with endometriosis [25].
Most studies have focused on the peritoneal fluid or
serum concentrations of the chemokine of interest rather
than its source. The latter may be important as the expres-
sion pattern of chemokines in the uterus is remarkably
cell-type specific [26]. In addition, the cellular origin of
chemokines also varies with cycle stage, although this also
differs between individual cytokines [26,27]. For exam-
ple, in the mid-secretory phase of the menstrual cycle,
many cytokines are produced predominantly by the epi-
thelial cells, while in the late secretory and menstrual
phases, the same cytokines are also strongly expressed in
both decidualised stromal cells and leukocytes [26,27],
normal peritoneum, peritoneal fluid immune cells, and
ectopic endometrial stromal cells [28]. This highlights the
importance of examining not just the entire tissue but spe-
cific cell types in any tissue where inflammatory cells are
abundant or where there are a number of different cell
types present. Likewise in disease pathologies including
endometriotic lesions, the diseased cells of interest, are
surrounded by healthy tissue elements and the cell types
of interest may constitute only a small proportion of the
volume of the tissue biopsy sample. Laser capture micro-
dissection (LCM) offers a means to overcome inaccuracies
arising from analysis of tissues in which there is consider-
able cellular heterogeneity or in which leukocytes are
abundant.
The strengths of two new technologies, LCM and gene
array, were utilized in the present study to achieve two
main aims. Firstly, to identify chemokines that are differ-
ently expressed in glands in eutopic endometrium from
normal women and those with endometriosis and sec-
ondly, to establish whether these chemokines are also
present in glands in endometriotic lesions. Understand-
ing the pathophysiology of chemokine secretion in
endometriosis is important as it may offer a novel area of
therapeutic intervention. Inhibiting the secretion or
action of specific chemokines or blocking their receptors
could prevent the inappropriate recruitment of leukocytes
to sites of endometriosis-related inflammation. This
approach could be considered to act upstream of anti-
inflammatory therapies available today which, for the
most part, act on the cells already at the site of inflamma-
tion.
Methods
Patient details and tissue collection
Patients undergoing laparoscopy for pelvic pain, investi-
gation of infertility or tubal ligation were recruited at
Monash Surgical Private Hospital and at Monash Medical
Centre, Moorabbin and Cranbourne Campus, all in
greater Melbourne, Australia. Ethical approval wasReproductive Biology and Endocrinology 2007, 5:18 http://www.rbej.com/content/5/1/18
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obtained from appropriate institutional ethics commit-
tees and informed consent was obtained prior to surgery.
Control subjects were those with no laparoscopic evi-
dence of endometriosis. Endometriosis patients were
assessed according to the revised American Society of
Reproductive Medicine classification system [29]. Eutopic
endometrium was obtained from both control and
endometriosis patients by standard curettage. Ectopic
endometriotic tissue was obtained via laparoscopic exci-
sion. Areas biopsied included peritoneum, uterosacral lig-
aments, and the ovary (endometriomata). Women on any
hormonal preparations were excluded from the study.
Patient details are provided in Table 1.
Eutopic endometrial tissue sections were designated to
menstrual cycle stage by an experienced gynecological
pathologist using the established Noyes endometrial dat-
ing criteria [30]. For this study, selected tissue samples,
derived only from women in the mid-secretory phase
(POD 6–10) were assessed for chemokine expression.
Endometrial curettings (eutopic tissue) and endometri-
otic biopsies were snap frozen immediately at -80°C in
OCT embedding medium (Sakura Finetek USA Inc., Tor-
rance CA, USA) and stored at -80°C until use.
Tissue preparation for laser capture microdissection
Sectioning of frozen tissue samples and processing of sec-
tions were performed using methods described previously
[31]. Frozen tissue blocks were maintained at -20°C and
sectioned at 10 μm, and sections adhered to sterile glass
slides (uncharged and uncoated; Objektträger, HD Scien-
tific, Melbourne, Australia) by gentle warming of the slide
undersurface and then refreezing at -20°C. Sections were
then fixed in cold (0°C) acetone for 1 min, stained with
HistoGene (Arcturus Bioscience Inc., CA, USA) for 1 min
and dehydrated in 95% ethanol (1 wash, 30 sec), 100%
ethanol (three washes, 30 sec each) and xylene (two
washes, 5 min each). Sections were then allowed to air dry
at room temperature and used for laser capture microdis-
section.
Laser capture microdissection
Laser capture microdissection (LCM) was used for the iso-
lation of epithelial glands from endometrial eutopic tis-
sue samples. Frozen tissue sections from patients with
endometriosis (n = 4, marked * in Table 1) and control
subjects (n = 4) were used for LCM. The PALM® MicroLaser
Microdissection System (P.A.L.M. MicroLaser Technolo-
gies AG, Burnried, Germany) was utilized. Staining of fro-
zen sections with HistoGene™ (Arcturus Bioscience Inc.,
CA, USA) enabled the precise selection of the glandular
structures. The laser dissected glands were then ejected off
the slide with a single defocused laser pulse and cata-
Table 1: Clinical characteristics of endometriosis subjects.
Endometriosis Patients
Case reference Age (yr) AFS stage Sites of endometriotic lesions Gravidity Parity
1*# 40 II Peritoneal 6 4
2*# 28 I Uterosacral 0 0
3*# 28 II Peritoneal, Uterosacral 0 0
4* 29 II Peritoneal, Uterosacral 0 0
52 7 V U t e r o s a c r a l 0 0
6 37 V Ovarian 1 1
7 28 V Ovarian, Uterosacral, Pouch of Douglas 1 0
8 35 III Ovarian 1 1
9 37 IV Peritoneal 0 0
10 37 II Peritoneal 7 4
Control Subjects
Case reference Age (yr) AFS stage Sites of endometriotic lesions Gravidity Parity
1*# 42 0 - 0 0
2*# 46 0 - 3 3
3*# 30 0 - 4 2
4* 32 0 - 0 0
AFS, American Fertility Society
*used in cDNA array analysis (amplified RNA)
# used in real-time PCR analysis (unamplified RNA)Reproductive Biology and Endocrinology 2007, 5:18 http://www.rbej.com/content/5/1/18
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pulted directly into the cap of a microfuge tube containing
10 μl droplet of TRIzol (Gibco BRL, Rockville, USA). For
each patient, epithelial glands were laser-captured from
approximately 20 tissue sections
RNA extraction and purification
Total RNA was isolated from each LCM sample using the
TRIzol method according to manufacturer's instructions
(Gibco BRL, Rockville, USA) following an initial incuba-
tion with glycogen (250 ng/μl) and TRIzol reagent for 30
min at room temperature to improve yields. RNA samples
were stored at -80°C.
RNA quantification
The RNA concentration for each sample was determined
with the RiboGreen fluorescence RNA assay (Molecular
Probes Europe BV, Leiden, The Netherlands) with an
Escherichia coli ribosomal RNA preparation of known con-
centration as standard and RiboGreen reagent at a final
dilution of 1:500. A standard curve of 0–80 ng/well in a
96-well flat-bottomed plate was employed. This assay
gave an intra-assay coefficient of variance (CV), as defined
by the repeated analysis of a single RNA sample, of 3.3%
(n = 16) and an inter-assay variation of 10.3% (n = 14).
To assess RNA quality and tissue specificity, RNA samples
were reverse transcribed and primers specific for a mid-
secretory phase endometrial gland-specific gene (HtrA3)
used for PCR amplification as previously described [32].
RNA amplification
Amplification of mRNA was performed to achieve the
required amount of RNA for cDNA gene arrays. To obtain
a representative molecular profile comparison of eutopic
endometrium in each of control and endometriosis sub-
ject groups, 5 ng of LCM glandular epithelial cell-derived
RNA from each of the 4 subjects in the group were pooled.
T7 specific RNA amplification of mRNA was performed
with the Arcturus HS RNA Amplification Kit (Arcturus)
according to manufacturer's instructions. Final RNA yields
following amplification, ranged from 0.5 μg to 1.5μg.
Gene array
Gene profiling was conducted using the GeArray Q Series
Human Chemokine and Receptor Gene Array (SuperArray
Bioscience Corp., Bethesda, USA) consisting of 77 chem-
okine and chemokine receptor cDNA probes, printed in
quadruplicate on a nylon membrane. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), cyclophilin and β-
actin were included as positive controls and PUC18 plas-
mid DNA as a negative control. The gene array experi-
ments were performed as previously described [27].
For each array experiment, 100 ng amplified RNA was
reverse transcribed to cDNA using Moloney murine leuke-
mia virus-reverse transcriptase (MLTV-RTase) (Promega,
Annandale, NSW, Australia) in the presence of bioti-
nylated uridine 5-triphosphate (udTP) (Roche), and incu-
bated overnight in hybridization buffer (SuperArray)
containing 100 μg/ml denatured sheared salmon sperm
DNA (Invitrogen Australia, Pty. Ltd., Mount Waverley,
Vic, Australia) with pre-hybridized nylon arrays at 68°C.
Post-hybridization washes with saline/sodium citrate/
sodium dodecyl sulfate (SSC/SDS) were also conducted at
68°C. Positive cDNA binding was detected by application
of a streptavidin-alkaline phosphatase conjugate in block-
ing solution and chemiluminescent substrate, CDP-Star as
supplied with the arrays (SuperArray).
Membranes were exposed to X-ray film for a range of
times between 2 sec and 5 min, to ensure quantitation
during the linear phase of the reaction. Arrays for the two
subject groups were conducted simultaneously, and the
entire experiment was then repeated. X-ray films were
scanned at high resolution and densitometrically ana-
lyzed using GelDoc software (Bio-Rad Laboratories,
Regents Park, NSW, Australia). Chemokine signals were
normalized for background signal intensity, to correct for
exposure times. Gene expression for each array was also
normalised to cyclophilin expression levels. Fold changes
in gene expression of 2-fold or higher were considered as
significantly different.
Real time RT-PCR
To confirm array data and to determine the variability
between subjects, real time RT-PCR was performed on
unamplified RNA derived from individual LCM samples
from endometriosis and control groups (n = 3 per group:
insufficient starting material was available for the remain-
ing 2 samples). Total unamplified RNA (5 ng) was reverse
transcribed using avian myeloblastosis virus-reverse tran-
scriptase (AMV-RTase) (Promega, NSW, Australia) and 1
ng random hexanucleotide primers (Amersham Bio-
sciences, NJ, USA), and the cDNA generated was subse-
quently amplified by PCR for specific primer pairs
encoding CCL16, CCL21 and 18S RNA genes (for primer
sequence refer to [27]).
The Roche Light Cycler Real-time PCR system was used
(Roche Diagnostics Australia Pty Ltd, NSW, Australia)
where 4 μl cDNA (diluted 1 in 10) was added to a master
mix including SYBR Green I, deoxynucleotide triphos-
phates, Taq polymerase enzyme, optimized concentra-
tions of MgCl2, and specific primers (0.5 pmol/μl; Sigma
Genosys, Australia Pty. Ltd., NSW, Australia). An initial
denaturing step was performed for 10 min at 95°C, before
40 cycles of 95°C for 15 sec, 55–66°C for 5 sec (annealing
temperature specific to primer pair [27]) and 72°C for 10
sec. All samples to be compared were included within the
same run and the entire PCR experiment was performed
in duplicate.Reproductive Biology and Endocrinology 2007, 5:18 http://www.rbej.com/content/5/1/18
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Expression of mRNA was quantitated by comparison with
a 6-point standard curve of serially diluted (10-fold)
cDNA standards specific to the gene product. The stand-
ard doses ranged between 2.5 ng/μl and 0.5 fg/μl. Fluores-
cence from incorporation of SYBR green into double-
stranded PCR products was monitored continuously dur-
ing cycling at the end of each elongation phase, and quan-
titation of mRNA expression was performed when
amplified products were in the log-linear phase and paral-
lel to the standards. A quality control (a single endome-
trial cDNA sample) was included in every run. At the end
of each program, melting curve analysis was carried out to
ensure specificity of the reaction products. The sizes of the
products were confirmed by gel electrophoresis and DNA
sequenced to confirm identity for selected samples. Data
was normalized for the expression of 18S RNA.
Immunohistochemistry
For the further verification of gene array and real time RT-
PCR data, frozen sections from 3 of the 4 same endome-
triosis patients and control subjects, along with tissue sec-
tions from an additional 8 normal and 7 endometriosis
subjects, were used for the immunohistochemical com-
parison of chemokine (CCL16 and CCL21) protein
expression (n = 12 and 10 respectively per group). Glands
were not found in the frozen endometriotic lesion of one
endometriosis patient who had been included in the array
study and this subject was thus excluded from this part of
the study. Affinity-purified polyclonal antibodies raised
against human CCL21 and CCL16 peptides (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) were utilized for
immunohistochemistry as previously described [27]. Pos-
itive controls (normal eutopic endometrium) previously
shown to have positive staining for CCL16 and CCL21,
were included in every run. Negative controls were sec-
tions of each tissue included on the same slide but with
non-immune IgG at the same concentration substituted
for the primary antibodies. For immunostaining, 10 μm
sections were post-fixed in 10% buffered formalin for 10
min, rehydrated and exposed to microwave antigen
retrieval for 5 min before cooling. Primary antibodies
were applied overnight (17 ± 1 h) at 4°C, diluted to 4 μg/
ml in non-immune block containing 10% horse serum
(Sigma-Aldrich, Sydney, Australia) and 2% human serum
(in-house) in TBS with 0.1% Tween 20.
Detection of positive binding was performed by the
sequential application of biotinylated horse anti-goat IgG
(1:200 in nonimmune block; Vector Laboratories, Burlin-
game, CA, USA) and avidin-biotin-peroxidase conjugate
(Dako, Glostrup, Denmark), followed by the substrate
diaminobenzidine (Dako) for between 2 and 10 min. Sec-
tions were counterstained with Harris' hematoxylin
(Sigma), dehydrated and mounted from Histosol with
DPX mounting medium (BDH Laboratory Supplies,
Poole, UK). Immunostaining was assessed semi-quantita-
tively by two independent assessors, blind to the identity
of subject groups. Blinding was not possible in the assess-
ment of ectopic tissue potentially biasing the results.
Staining intensity and heterogeneity for each endometrial
compartment (epithelium, stroma, leukocytes and vascu-
lature) was assessed and allocated a score between 0 and
4 where 0 = no stain, 1 = faint staining, 2 = moderate stain-
ing, 3 = strong staining and 4 = maximally intense stain-
ing.
Statistical analysis
None of the data were normally distributed and therefore
non-parametric tests were used. The direct comparison of
two samples from different patients was conducted with
the Mann-Whitney U-test. The direct comparison of two
samples (eutopic and ectopic endometrium) from the
same patient was conducted with the Wilcoxon Matched-
Pairs Signed-Ranks Test. For the relationship between two
independent interval variables (staining intensities for
CCL16 and CCL21) the rank correlation coefficient was
used. The significance level was set at a P value of < 0.05.
Results
Laser capture microdissection
Laser capture technology enabled the isolation of glandu-
lar epithelial cells from mid-secretory phase endometrial
tissue of control and endometriosis subjects (n = 4 per
group) (Figure 1A and 1B). For each subject, 150 – 600
glands were microdissected from 10 to 20 individual fro-
zen tissue sections of 10 μm in thickness. Extraction of
RNA of the LCM cells produced RNA yields of varying
quantities ranging from 0.18 ng to 1.15 ng per glandular
structure isolated (Figure 1C). The positive amplification
of the epithelial-specific gene product, Htra3, ascertained
that glandular epithelial cells had been specifically iso-
lated and RNA integrity retained (Figure 1C).
Gene array
To provide a global chemokine expression profile in
eutopic endometrium from normal women and endome-
triosis patients, and to overcome patient to patient varia-
bility, total RNA extracted from LCM glandular epithelial
cells was pooled from 4 individuals in each group (Table
1). Of 77 genes profiled on the cDNA gene arrays, expres-
sion of 22 chemokine and receptors were reproducibly
(two separate runs) upregulated in pooled endometrium
from women with endometriosis compared with controls
(Table 2). Downregulation of expression was observed in
11 genes; however only 2 of these demonstrated a 2-fold
or higher difference when compared to expression levels
in normal endometrium (Table 3). For many upregulated
genes, fold increase was not quantifiable, due to the lack
of detectable expression in the control pool compared to
very high expression in the endometriosis pool. In con-Reproductive Biology and Endocrinology 2007, 5:18 http://www.rbej.com/content/5/1/18
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trast, the fold-change quantified in genes which were
downregulated was relatively small, with the largest differ-
ence being a 2.5-fold decrease in CCL28 expression.
Real-time RT PCR
To verify the results obtained from cDNA array experi-
ments and to establish the variability between individu-
als, two candidate genes (CCL16 and CCL21, also known
as HCC-4 and 6C-kine respectively) that had not previ-
ously been identified as associated with endometriosis,
were selected for further analysis using quantitative real-
time RT-PCR on individual unamplified RNA samples of
glands from eutopic tissue (patients and controls: n = 3
subjects per cohort). All 3 samples used for each cohort,
in this analysis, were included in cDNA array analysis.
Selection of the candidate genes was based on the marked
upregulation of mRNA levels on the cDNA arrays. These
chemokines have been previously characterised in normal
cycling human endometrium in our laboratory [27], the
mRNA for CCL16 and CCL21 is maximal in entire
endometrium during the mid-secretory phase of the men-
strual cycle. In this study, mRNA expression for CCL16
was below the detection limit in the LCM glands from all
3 controls and 1 of the 3 endometriosis patient samples
(Figure 2A). Where detectable, expression levels ranged
from 0.01 – 0.05 fg/pg 18S RNA. Overall there was a sig-
nificant elevation in eutopic endometrial glandular
CCL16 expression in women with endometriosis com-
pared to controls (n = 3; P = 0.049).
CCL21 mRNA was more abundant than that of CCL16
and was markedly elevated in eutopic glands from one
endometriosis patient (mean, 0.61 fg/pg 18S RNA) (Fig-
ure 2B). The levels of CCL21 observed in the remaining
endometriosis patients ranged from 0.02 – 0.19 fg/pg 18S
RNA. In the control cohort, CCL21 mRNA expression
ranged between 0.003 – 0.045 fg/pg 18S RNA. These com-
bined data clearly show that the expression of CCL16 and
CCL21 is disturbed at least in some patients with endome-
triosis. In women without endometriosis the expression
was consistently low.
Chemokine immunohistochemistry in control and 
endometriosis eutopic tissue
Since the findings from the cDNA array and real time RT-
PCR experiments supported a role for CCL21 and CCL16
in at least some women with endometriosis, immunohis-
tochemistry was performed to establish the presence and
cellular location of the protein for these 2 chemokines in
eutopic and ectopic endometrial samples. Immunoreac-
tivity for both chemokines was evident in glandular epi-
thelial cells but absent from stromal cells and was overall
in accord with the real-time PCR quantitation. CCL16
protein was detected in the glandular epithelium of all but
one of the 32 tissues examined and CCL21 protein was
evident in glands in all tissues. However, staining was var-
iable between individual tissues even within groups (Fig-
ure 3). No significant differences were detected for either
CCL16 or CCL21 between mean glandular staining inten-
sity in endometrium from normal women compared with
eutopic endometrium from women with endometriosis
(Figure 3). The staining pattern in some glands was pre-
dominantly apical (Figures 4A–C) suggesting secretion of
the chemokine into the uterine lumen. Within each tissue,
all glands were equally stained and staining was present in
all cells in each gland (Figures 4A–D).
Chemokine immunohistochemistry in matched eutopic 
and ectopic endometriosis tissue
Comparisons were also made between the immunostain-
ing in matched eutopic and ectopic endometrium in
endometriosis patients. Positive staining was present in
ectopic tissue for both CCL16 and CCL21 (Figures 3 and
4). In both cases, chemokines specifically localised in epi-
thelial cells of glandular structures in ectopic lesions
Laser capture microdissection Figure 1
Laser capture microdissection. (A) Frozen section of 
eutopic endometrial tissue from an endometriosis patient 
(mid-secretory phase) stained with HistoGene™. The epi-
thelial glands were isolated with laser capture microdissec-
tion (LCM). (B) Tissue section following LCM demonstrating 
the precision in dissection and cell capture. (C) RNA yields 
from microdissected glands expressed as total RNA (ng) per 
number of gland from each tissue sample. Microdissected 
glandular RNA samples from control (C, n = 4) and endome-
triosis (E, n = 4) tissues were separately, reverse transcribed 
and a uterine epithelial cell-specific gene (HtrA3) was ampli-
fied using PCR to assess RNA quality (insert).Reproductive Biology and Endocrinology 2007, 5:18 http://www.rbej.com/content/5/1/18
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derived from ovarian, uterosacral ligaments and perito-
neal sites. In some ectopic peritoneal lesions, large irregu-
lar cyst-like structures were present and strong staining for
both CCL16 and CCL21 was apparent in glandular epithe-
lial cells and in secretions within the cyst. In other perito-
neal lesions, but more commonly, in ovarian lesions,
glandular formation was very structured, closely resem-
bling eutopic tissue morphology. Very strong staining was
seen in glands in some ectopic lesions (one lesion for
CCL16 (Figure 4E) and three for CCL21). Overall glandu-
lar staining intensity was higher in ectopic tissue than in
eutopic tissue and this reached significance (P = 0.047) for
CCL16. Importantly, there was a high degree of correla-
tion between staining for CCL16 and CCL21 in each sam-
ple (Rank correlation coefficient R = 0.81, P < 0.001).
Leukocytes were evident in most tissues and stained
strongly for CCL16 and CCL21: these were highly abun-
dant in some lesions (Figure 4F insert) emphasizing the
importance of laser capture microdissection in this study.
Inclusion of leukocytes in the original cDNA array analy-
sis would have skewed the data. As negative controls,
endometrial sections with non-immune IgG substituted
for the primary antibodies, demonstrated no localised
staining (Figures 4G–H).
Discussion
This study used laser capture dissection and pathway-spe-
cific gene array analysis to determine chemokines that
may be expressed at elevated levels during the mid-secre-
tory phase in the glandular epithelium of the
endometrium of women with endometriosis when com-
pared to controls. Using pooled samples, 22 genes were
markedly upregulated while only 2 genes were slightly
downregulated in the endometriosis cohort. Real-time
PCR verified that there were differences in the mRNA
encoding CCL16 and CCL21, the two chemokines
selected for further study, but that there was considerable
heterogeneity in expression in individual endometriosis
subjects. This heterogeneity was confirmed at the protein
level. Furthermore, immunoreactive CCL16 was more
intensely stained in epithelium in ectopic endometriosis
lesions compared with matched eutopic tissue, and there
was a similar trend for CCL21. Indeed, there was high cor-
relation between staining for these two chemokines in
each sample. This data thus adds CCL16 and CCL21 to the
chemokines found to be elevated in endometriosis sup-
Table 2: Upregulated genes in glandular epithelial cells of eutopic endometrium: endometriosis compared with controls.
Regulated gene 
for chemokines
Common name Fold change Associa-ted with 
receptors
Functional expression on immune 
cells
Gene accession
CCL15 HCC2 ++ CCR1, CCR3 T-lymphocytes, monocytes NM_004167
CCL16 HCC4 ++ CCR1 Monocytes NM_004590
CCL18 PARC ++ unknown T-lymphocytes NM_002988
CCL19 MIP-3β ++ CCR7 T-cell and B-lymphocytes. NM_006274
CCL21 6Ckine ++ CCR7 Leukocytes, endothelial cells NM_002989
CCL22 MDC 2.2 (1.6, 2.9) CCR4 Leukocytes, natural killer cells NM_002990
CCL23 MPIF-1 ++ CCR1 T-cell lymphocytes, Monocytes, 
Neutrophils
NM_001295
CXCL5 ENA-78 2.1 (1.5, 2.6) CXCR2 Works in conjunction with IL8 to activate 
neutrophils
NM_002994
CXCL8 IL8 2.2 (1.5, 2.5) CXCR2 T-cell lymphocyte and neutrophil 
chemoattractant
NM_000584
CXCL10 I-P10 ++ CXCR3 Monocytes, natural killer cells, T-cell 
lymphocytes
NM_001565
CXCL13 BCA-1 3.0 (1.9, 3.7) CXCR5 B- and T-cell lymphocytes NM_006419
XCL1 lymphotactin ++ XCR1 B- and T-cell lymphocytes NM_005283
XCL2 SCM-1β ++ XCR1 T-cell lymphocytes NM_003175
CX3CL1 Fractalkine 16.4 (2.2, 30.6) CX3CR1 T cells, monocytes NM_002996
Receptors Ligand
CCR1/CD234 Duffy antigen receptor for 
chemokines (DARC)
2.2 (1.5, 2.6) CXCL1, CXCL5, CXCL8 Erythrocytes, leukocytes, Endothelial cells NM_002036
CCR10 GPR2 ++ CCL27 T-cells NM_016602
CXCR2 IL-8Rβ ++ CXCL8 Neutrophils NM_001557
CXCR4 fusin ++ CXCL12 T-and B-cell lymphocytes, monocytes, 
macrophages
NM_003467
CXCR5 BLR1 2.5 (2, 2.8) CXCL13 B- and T-cell lymphocytes NM_001716
CXCR6 TYMSTR 5.8 (4.1, 7.5) CXCL16 T-cell lymphocytes NM_006564
XCR1 GPR55 ++ XCL1 XCL2 T cells, mast cells, monocytes, macrophages NM_005283
LTB4R* GPR16 1.9 (1.4, 42.2) leukotriene B4 (LTB4) Neutrophils NM_181657
++ Fold upregulation > 20 fold; in most cases cDNA hybridization signal was undetectable in control arrays but clearly detectable in endometriosis 
arrays. Where difference in expression was quantifiable and variable between the 2 arrays, fold change is presented in parentheses.
*not a chemokine receptor, is a potent chemoattractant and survival factor for neutrophilic polymorphonuclear (PMN) leukocytes (59, 60)Reproductive Biology and Endocrinology 2007, 5:18 http://www.rbej.com/content/5/1/18
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porting a role for chemokines in the pathogenesis of
endometriosis. Given the small patient cohort assessed,
definitive conclusions cannot be drawn: however the cur-
rent study provides preliminary data on the involvement
of previously unidentified chemokines in the pathogene-
sis of endometriosis.
Despite the technical difficulties in obtaining sufficient
quantities of mRNA with LCM, the current study clearly
highlights the importance of laser capture microdissection
for the accurate analysis of cell-specific gene expression in
heterogeneous tissues such as endometrium. In this tis-
sue, epithelial cells are the predominant source of chem-
okines [27], many of which are maximally expressed in
the mid secretory phase. However, both decidualized stro-
mal cells (found only in late secretory endometrium) and
leukocytes are variably abundant in endometrium
throughout the menstrual cycle and are additional sources
of chemokines. By isolation and initial analysis of glandu-
lar epithelium from endometrium, we have been able to
identify epithelial-derived chemokines and have excluded
the variability and likely spurious results that would have
been caused by the presence of infiltrating leukocytes,
which also produce chemokines [27].
Laser capture microdissection and RNA amplification
technology have been used previously for gene expression
profiling of the glandular epithelium in endometriosis
patients and aberrant expression was noted in genes relat-
ing to oxidative stress and focal adhesion and in genes
linked to Wnt, PI3K and RAS/RAF/MAPK signalling [33-
35]. As there are no reports of chemokine expression pro-
filing in endometriosis, the present study is the first to
provide a comprehensive list of potential candidate chem-
okines and receptors in laser-captured glandular epithe-
lium in eutopic endometrium from women with
endometriosis.
Selected chemokines identified as being of potential inter-
est from the array analysis were further examined by semi-
quantitative real-time PCR analysis. Importantly, individ-
ual samples were assessed at this stage, to establish not
only the variability between the two study groups, but
also that between individuals. In laser captured glands
from control subjects, CCL16 and CCL21 mRNA were
uniformly undetectable or at low levels. In contrast, in
women with endometriosis, eutopic CCL16 and CCL21
mRNA levels were increased in some subjects but with sig-
nificant patient-to-patient variability. This variability
could be attributed both to the heterogeneity of the dis-
ease, both in cause and phenotype and also to differences
in endometrial morphology from individual to individ-
ual. Subsequent immunohistochemical examination of
the protein however, showed somewhat different results.
More tissues were used for this analysis and staining
intensities of the two chemokines in the glands were very
variable between individuals. Interestingly the major dif-
ferences in protein were seen between eutopic and ectopic
tissues in the same women, with overall higher staining
intensity in ectopic tissue. The discrepancy between
mRNA and protein levels may reflect either rapid clear-
ance of mRNA or the stability of immunoreactive protein.
The precise roles of CCL16 and CCL21 in the
endometrium are currently unknown, but there is consid-
erable information regarding their functions in immuno-
logical disease and cancer. CCL16 is specifically
chemotactic for monocytes [36-38]. It increases antigen
presentation of macrophages, enhances T-cell cytotoxicity
and stimulates their production of a number of inflamma-
tory-type cytokines (IL-1β, TNFα, IL-12) [37]. A recent
study showed that CCL16 stimulated cell migration of
human osteogenic sarcoma cells expressing CCR1 [39]. It
is also found to be overexpressed in synovial tissue from
patients with inflammatory joint disease [40]. CCL16 has
low sequence homology (30%) to other CCR1-dependent
chemokines, and significant structural differences, partic-
ularly in the N-terminal region required for receptor acti-
vation [41]. This may explain why CCL16, although
binding to a non-specific receptor, triggers a unique sig-
nalling cascade and provides evidence of differential regu-
latory mechanisms employed by chemokines to illicit
cellular responses.
CCL21 has known functions in homeostasis, in the recon-
stitution of lymphocytes and in immuno-surveillance
[42]. It activates T-cells and lymphocytes [43], attracts
both T- and B-cells and dendritic cells (DC) to lymphoid
tissues through its receptor CCR7. It is essential for the
priming of naive T-cells in the initiation phase of the
immune response [44,45]. CCL21 has also been impli-
cated in the abnormal adhesion and migration of CD34+
cells in leukemia [46]. How an elevation of CCL21 may
contribute to endometriosis is not certain. However, ele-
vations in expression of this normally constitutive chem-
okine have been reported in cases of chronic
inflammation/pathology and autoimmune diseases
where a role in inappropriate recruitment of naïve T-cells
to non-lymphoid tissue has been proposed [47,48]. Inter-
estingly, endometriosis has been likened to an autoim-
mune disease [49].
In addition to their upregulation in eutopic endometrium
from women with endometriosis, examination of CCL16
and CCL21 in ectopic tissues demonstrated a significant
increase in protein relative to expression in eutopic tissue
derived from the same individual. A similar observation
has been documented recently with the induction of
endometriosis in a baboon model with no prior disease
[50]. Following the inoculation of endometriosis tissueReproductive Biology and Endocrinology 2007, 5:18 http://www.rbej.com/content/5/1/18
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into the peritoneal cavity of the animal, a concomitant
increase in cysteine-rich angiogenic inducer 61 (CYR61)
gene expression was measured both in eutopic and
ectopic tissues. This observation suggests it is the presence
of the endometriotic lesions, which directly influences the
local environment in the endometrium. In our immu-
nolocalization study of the ectopic lesions, typical large
cyst-like structures containing much cellular debris/secre-
tion strongly stained for the chemokines, suggesting secre-
tion of chemokines apically from the epithelial cells.
However, the level of chemokine expression did not cor-
relate with the severity of the endometriosis.
CXCL8 (IL-8), another chemokine whose mRNA was
increased in endometrial glands from women with
endometriosis in our array study, has previously been
studied in depth with regard to a role in endometriosis
[51], further substantiating our gene array results. CXCL-8
levels are elevated in peritoneal fluid in women with
endometriosis [51-53]. Furthermore, glandular epithelial
cell localisation and upregulation of immunoreactive
CXCR1 and CXCR2, which bind CXCL8, has been demon-
strated in eutopic and ectopic tissue sections from
endometriosis patients when compared to controls [54].
The data from this pathway-specific gene array thus pro-
vides new evidence for the broad dysregulation of chem-
okine expression in both eutopic endometrial epithelium
and ectopic lesions of women with endometriosis. The
glandular chemokines which were upregulated are known
to recruit and activate natural killer cells, T and B lym-
phocytes, monocytes and neutrophils. Collectively, such
upregulation of chemokines and receptors, in endometri-
osis patients may demonstrate an increased ability of the
endometrium and endometriotic lesions to recruit leuko-
cytes and thus exacerbate the inflammatory response.
Table 3: Downregulated genes in glandular epithelial cells of eutopic endometrium: endometriosis compared with controls.
Regulated gene for 
chemokines
Common name Fold change Associated receptor Functional expression on immune cells Gene accession
CCL28 MEC 2.5 (1.1 – 1.7) CCR10 T-cell lymphocytes, Eosinophils, NM_019846
CCL4 MIP1β/ACT-2 2.0 (1.3 – 3.3) CCR6 B- and T-cell lymphocytes, neutrophils, macrophages, 
monocytes
NM_002984
Real-time PCR quantitation of CCL16 and CCL21 mRNA expression in control and endometriosis subjects Figure 2
Real-time PCR quantitation of CCL16 and CCL21 mRNA expression in control and endometriosis subjects. (A) 
mRNA expression of CCL16 and (B) CCL21 was measured in glandular RNA samples from individuals in control (■) and 
endometriosis cohorts (■, ●, ▲ representing the 3 patients' individual data). Data is presented as relative units where chem-
okine expression has been normalized to 18S RNA expression for each sample (n = 3 per group, RT-PCR performed in dupli-
cates). The average value for each subject group is indicated with a horizontal line. * denotes a statistically significant difference 
between the 2 groups (P = 0.049, Mann-Whitney U-test).
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Aberrant chemokine expression in the uterine lumen may
interfere with blastocyst implantation and hence provide
one rationale for the infertility that is often associated
with endometriosis. The invasive trophoblast and the
eutopic endometrium strongly express chemokine recep-
tors (CCR1, CCR10, CCR5, CCR7, CXCR4, CXCR6 and
XCR) and chemokines contribute to the positioning,
adhesion and migration of trophoblast [55-58]. Chemok-
ines also have non-immune functions during tissue
remodelling and in many diseases through upregulation
of adhesion molecule expression, angiogenesis, cell pro-
liferation and motility [59]. The higher abundance of
chemokines in endometriosis may facilitate tissue adher-
ence of retrograde menstrual tissue, increase epithelial cell
proliferation and remodelling to form glandular struc-
tures, and stimulate tissue breakdown and bleeding. There
is some functional evidence in support of a role of chem-
okines in increasing tissue adherence. In a recent study,
treatment of mice with a broad-spectrum chemokine
inhibitor (NR58-3.14.3) reduced the size and number of
post-operative intra-peritoneal adhesions [60] and in par-
ticular, a reduction in CD45+ inflammatory cell accumu-
lation within the adhesions was observed.
Conclusion
In conclusion, the current study has identified potential
new candidate molecules from the chemokine family that
may be important in the pathogenesis of endometriosis.
The use of laser capture microdissection was fundamental
to identify only those chemokines and chemokine recep-
tors derived from the epithelial compartment. Further,
two novel candidate molecules, CCL16 and CCL21, not
previously linked to endometriosis have been validated.
This data supports the hypothesis that the inflammatory
phenotype observed in endometriosis may involve the
activation of chemokine cascades.
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Immunostaining for CCL16 and CCL21 Figure 4
Immunostaining for CCL16 and CCL21. Representative tissues immunostained for CCL16 (A, C, E) and CCL21 (B, D, F). 
CCL16 and CCL21 staining, in control eutopic endometrial tissue (A, B), eutopic tissue (C, D), and matched ectopic lesions (E, 
F) from the same endometriosis patient. Leukocytes stained for CCL21 are shown in the insert in (F). (G, H) Endometrial sec-
tions with non-immune IgG substituted for the primary antibodies, as negative controls. Scale bars represent 200 μm.
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